A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a dose escalation, and dose expansion study of T-DXd plus hyaluronidase administered subcutaneously, to assess the safety, tolerability, PK and efficacy of SC T-DXd plus hyaluronidase in participants with metastatic solid tumors.